Status:
RECRUITING
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Aarhus University Hospital
Hvidovre University Hospital
Conditions:
Primary Biliary Cirrhosis
Eligibility:
All Genders
18-99 years
Brief Summary
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis ...
Detailed Description
Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease characterized by destruction of intrahepatic bile ducts and progression to liver fibrosis and cirrhosis. The diagnosis of P...
Eligibility Criteria
Inclusion
- PBC patient offered bezafibrate treatment
Exclusion
- patient age under 18
- life expectancy less than 6 months
- known cancer
- planned liver transplantation within 6 months
- other liver disease (viral, autoimmune, alcohol, NAFLD/NASH)
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04514965
Start Date
October 1 2020
End Date
September 1 2026
Last Update
August 12 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
Aarhus N, Central Jutland, Denmark, 8200
2
Department of Medicine, Gastrounit Medical division
Hvidovre, Denmark, 2650